U.S. taxpayers spent billions developing Ozempic-type diabetes and weight-loss drugs — now those drugs’ markups could ...

Novo Nordisk (NVO) plans to study how its GLP-1 drugs marketed as Wegovy and Ozempic for obesity and diabetes can help tackle ...

Novo Nordisk will explore how GLP-1 drugs could help patients struggling with addiction, its head of development Martin Holst ...

Novo Nordisk announced launching a direct-to-patient online pharmacy NovoCare, offering a more than half-price cut for its ...

Novo Nordisk A/S (NVO) has lowered prices of its blockbuster drug Wegovy for U.S. customers through a new direct-to-consumer online pharmacy, ...

Novo Nordisk 's ( NVO 3.84%) latest move in the retail sphere was met with approval from market participants Wednesday. They bid the stock up by nearly 4% following the company's news, a performance ...

Pharmaceutical manufacturer Novo Nordisk on Wednesday announced it will be offering a direct-to-patient program for uninsured ...

Makers of the popular obesity treatments Wegovy and Zepbound are cutting prices for people without insurance. Danish ...

Novo Nordisk is lowering the price of its weight-loss drug Wegovy to $499 per month for some patients paying out of pocket. The deal is available through the drugmaker's new NovoCare Pharmacy offering ...

Eli Lilly is offering vials of its weight-loss drug Zepbound to patients at a discount — but only if they skip their ...

Some commercially insured patients stand to save $150 per month on Wegovy, a popular obesity medication. Patients on Medicare ...

Novo Nordisk said Wednesday it will sell Wegovy for $499 a month in cash to patients who can’t get the blockbuster weight-loss drug through insurance, a bid to reach consumers who can’t afford the $1, ...